Prelude Therapeutics Incorporated

NasdaqGS:PRLD 주식 보고서

시가총액: US$52.9m

Prelude Therapeutics 관리

관리 기준 확인 3/4

Prelude Therapeutics CEO는 Kris Vaddi, Feb2016 에 임명되었습니다 의 임기는 8.75 년입니다. 총 연간 보상은 $ 2.64M, 21.7% 로 구성됩니다. 21.7% 급여 및 78.3% 보너스(회사 주식 및 옵션 포함). 는 $ 2.08M 가치에 해당하는 회사 주식의 3.93% 직접 소유합니다. 2.08M. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 4.5 년입니다.

주요 정보

Kris Vaddi

최고 경영자

US$2.6m

총 보상

CEO 급여 비율21.7%
CEO 임기8.8yrs
CEO 소유권3.9%
경영진 평균 재임 기간2.9yrs
이사회 평균 재임 기간4.5yrs

최근 관리 업데이트

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Oct 18

Prelude downgraded at Morgan Stanley ahead of key update

Sep 09

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16
What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25
Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

CEO 보상 분석

Kris Vaddi 의 보수는 Prelude Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$132m

Jun 30 2024n/an/a

-US$130m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$573k

-US$122m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$117m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$558k

-US$115m

Sep 30 2022n/an/a

-US$120m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$7mUS$544k

-US$112m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$69m

Dec 31 2020US$12mUS$417k

-US$57m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$315k

-US$28m

보상 대 시장: Kris 의 총 보상 ($USD 2.64M )은 US 시장( $USD 653.78K ).

보상과 수익: Kris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kris Vaddi (58 yo)

8.8yrs

테뉴어

US$2,641,789

보상

Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...

리더십 팀

이름위치테뉴어보상소유권
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Edna Huang
President & Chief Medical Officer2.6yrsUS$1.65m0.12%
$ 60.9k
Bryant Lim
Interim CFO1.8yrsUS$1.67m0.0044%
$ 2.3k
Aimee Crombie
Senior VP and Head of Strategic Planning & Operations2.8yrs데이터 없음데이터 없음
Madhu Pudipeddi
Senior Vice President of Technical Operations3.8yrs데이터 없음데이터 없음
Peggy Scherle
Chief Scientific Officer6.6yrsUS$1.63m0.33%
$ 173.8k
Lindsey Trickett
Vice President of Investor Relationsno data데이터 없음데이터 없음
Michele Porreca
Chief People Officer3.4yrs데이터 없음데이터 없음
Andrew Combs
Executive VP & Chief Chemistry Officer5.6yrsUS$2.63m0.57%
$ 300.1k
Naveen Babbar
Senior Vice President of Translation Medicine2.9yrs데이터 없음데이터 없음
William Novotny
Senior Vice President of Clinical Development2.2yrs데이터 없음데이터 없음
Wan-Jen Hong
Senior Vice President of Clinical Development2.1yrs데이터 없음데이터 없음

2.9yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: PRLD 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Julian Baker
Independent Director3.8yrsUS$140.03k0%
$ 0
Paul Friedman
Independent Chairman of the Board8.3yrsUS$161.03k0.91%
$ 480.9k
Martin Babler
Independent Director3.3yrsUS$134.53k0%
$ 0
David Bonita
Independent Director8.3yrsUS$144.53k0%
$ 0
Mardi Dier
Independent Director4.3yrsUS$147.03k0.018%
$ 9.6k
Victor Sandor
Independent Director4.5yrsUS$131.03k0%
$ 0

4.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: PRLD 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.